CD24 and neoplasm: Increasing trials is focusing on the strategy not only on blocking the CD24 on the surface of tumor cells, but also on targeting the CD24 and Siglec-10 genes, as well as targeting on the binding of CD24-Siglec-10 signal pathway (new insight and strategy in tumor immunity therapy field).